NCT06387862View on ClinicalTrials.gov

Pharmacokinetics of Inhaled Levosimendan

PHASE2RecruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

November 30, 2024

Study Completion Date

January 31, 2025

Conditions
Left Ventricular Dysfunction
Interventions
DRUG

Levosimendan 2.5 milligram/milliliter Injectable Solutiondose Inhaled

Each patient will receive 12µg/kg of levosimendan by inhalation over 10 min. During 10h following inhaled dose, plasma concentrations will be measured.

DRUG

Levosimendan 2.5 milligram/milliliter Injectable Solutiondose Intravenous

Each patient will receive 12µg/kg of levosimendan by intravenous (IV) administration over 10 min and at the same timepoints plasma samples will be measured

Trial Locations (1)

1090

RECRUITING

UZ Brussel, Brussels

All Listed Sponsors
lead

Universitair Ziekenhuis Brussel

OTHER